Mandate

Vinge advises management sellers in the USD 1.45 billion sale of AR Packaging Group AB

May 20, 2021 M&A

Vinge is advising management sellers in the USD 1.45 billion sale of AR Packaging Group AB (publ) (“AR Packaging”) to Graphic Packaging International Europe Holdings B.V (“Graphic Packaging”).

With over 4,700 employees and with decades of experience all across the globe within the packaging industry, AR Packaging brings together diverse talent and specialized knowledge to help their customers achieve success through packaging.

Graphic Packaging, headquartered in Atlanta, Georgia, and listed on the New York Stock Exchange, is a leading provider of paper-based packaging solutions with over 19,000 employees.

Closing of the transaction is subject to applicable competition law approvals and other customary closing conditions.

 

The Vinge team includes partner Magnus Hedsund, counsel Emelie Svensäter Jerntorp and associate Erik Ax.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024